Gotham Asset Management Boosts Stake in Organon & Co.

Investment firm increases holding in pharmaceutical company by over 37%

Mar. 16, 2026 at 10:39am

Got story updates? Submit your updates here. ›

Gotham Asset Management LLC, a major investment firm, has increased its stake in Organon & Co. (NYSE: OGN) by 37.2% in the third quarter, according to a recent SEC filing. The firm now owns 3,713,204 shares of the pharmaceutical company's stock, representing approximately 1.43% ownership.

Why it matters

Organon & Co. is a relatively new publicly traded company, having been spun off from Merck & Co. in 2021. The increase in Gotham Asset Management's stake suggests the investment firm sees significant potential in Organon's portfolio of women's health, biosimilar, and established brand products.

The details

According to the SEC filing, Gotham Asset Management acquired an additional 1,007,691 shares of Organon & Co. during the third quarter, bringing its total ownership to 3,713,204 shares. This represents a 37.2% increase in the firm's stake in the company.

  • Gotham Asset Management increased its stake in Organon & Co. during the third quarter of 2026.

The players

Gotham Asset Management LLC

A major investment firm that has increased its stake in Organon & Co. by over 37%.

Organon & Co.

A pharmaceutical company that was spun off from Merck & Co. in 2021, focusing on women's health, biosimilars, and established brand products.

Got photos? Submit your photos here. ›

The takeaway

Gotham Asset Management's increased investment in Organon & Co. suggests the firm sees strong potential in the company's product portfolio and growth prospects as an independent publicly traded entity.